We are live on ! Find out more
312.15 USD
-2.05
0.65%
At close Updated Oct 9, 4:00 PM EDT
Pre-market
After hours
311.84
-0.31
0.1%
1 day
-0.65%
5 days
1.32%
1 month
-2.79%
3 months
12.43%
6 months
14.23%
Year to date
24.04%
1 year
12.37%
5 years
32.5%
10 years
161.21%
 

About: Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.

Employees: 71,000

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 47.7%
Neutral 47.7%
Negative 4.5%
Positive
Zacks Investment Research
5 days ago
Here's Why Labcorp Holdings (LH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Labcorp Holdings (LH) is a Strong Value Stock
Neutral
PRNewsWire
11 days ago
Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026
BURLINGTON, N.C., Sept. 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc.
Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026
Neutral
Zacks Investment Research
12 days ago
Is This the Right Time to Add Labcorp Stock to Your Portfolio?
LH expands specialty testing and consumer services through acquisitions, partnerships and AI, while reimbursement and cost risks remain.
Is This the Right Time to Add Labcorp Stock to Your Portfolio?
Neutral
Seeking Alpha
18 days ago
Labcorp: The CMS Selloff Represents An Excellent Opportunity - Strong Buy
Labcorp shares dropped sharply after CMS released preliminary 2027 lab-payment rates, aligning Medicare rates closer to private insurers and targeting $1B annual savings. I see the selloff as overdone, with market fears exaggerated by a misunderstanding of the CMS report's impact on LH's bottom line. The proposed cuts only affect Medicare's Clinical Laboratory Fee Schedule, with annual reimbursement reductions capped at 15% and final rates pending.
Labcorp: The CMS Selloff Represents An Excellent Opportunity - Strong Buy
Positive
Seeking Alpha
19 days ago
Labcorp's Future Driven By Clinical Testing Demand, Despite Impact From Medicare Cuts
Labcorp Holdings Inc. is upgraded to Buy, supported by resilient demand for diagnostics and robust Q2 results, despite upcoming Medicare rate cuts. LH outperformed both the S&P 500 and healthcare peers YTD, with strong technical support and positive operating margins. Revenue durability, new test launches, and a diversified biopharma segment bolster LH's growth and risk profile amid regulatory headwinds.
Labcorp's Future Driven By Clinical Testing Demand, Despite Impact From Medicare Cuts
Negative
The Motley Fool
19 days ago
Why Labcorp Holdings Stock Dropped Today
Medicare and Medicaid have been overpaying Labcorp for years, says the government. Starting next year, they plan to cut reimbursement of lab testing by 15%.
Why Labcorp Holdings Stock Dropped Today
Neutral
Seeking Alpha
26 days ago
Labcorp Holdings Inc. (LH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Labcorp Holdings Inc. (LH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Labcorp Holdings Inc. (LH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neutral
Seeking Alpha
1 month ago
Labcorp Holdings Inc. (LH) Analyst/Investor Day Transcript
Labcorp Holdings Inc. (LH) Analyst/Investor Day Transcript
Labcorp Holdings Inc. (LH) Analyst/Investor Day Transcript
Positive
Benzinga
1 month ago
Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029
Labcorp Holdings (NYSE:LH) on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day.
Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029
Neutral
PRNewsWire
1 month ago
Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
Reaffirms full-year 2026 guidance Provides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to 11.5% Outlines strategic growth priorities driven by a differentiated platform powered by science, technology and global scale Presents long-term value creation framework driven by sustainable growth, strong cash flow generation and disciplined capital deployment BURLINGTON, N.C., Sept. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today will host its 2026 Investor Day at 9 a.m.
Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
Price charts implemented using Lightweight Charts™